Tags

Type your tag names separated by a space and hit enter

Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.
Travel Med Infect Dis. 2020 May - Jun; 35:101735.TM

Abstract

The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19.

Authors+Show Affiliations

Department of Medical Microbiology and Parasitology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Vaccines and Immunnotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: amhashem@kau.edu.sa.Department of Physiology, Neuroscience Unit, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia; Pre-Clinical Research Unit, King Fahad Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: basalghamdi@kau.edu.sa.Department of Medical Laboratories Technology, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia; Medical Research Center, Jazan University, Jazan, Saudi Arabia. Electronic address: AAlgaissi@jazanu.edu.sa.Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia. Electronic address: fsshehri@uqu.edu.sa.Department of Medicine, Faculty of Medicine, Imam Mohammed Ibn Saud Islamic University, Riyadh, Saudi Arabia. Electronic address: aibukhari@imamu.edu.sa.Vaccines and Immunnotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; Faculty of Pharmacy; King Abdulaziz University, Jeddah, Saudi Arabia. Electronic address: maalfaleh@kau.edu.sa.King Saud Medical City, Research & Innovation Center, Ministry of Health, Saudi Arabia; Al-Faisal University, Riyadh, Saudi Arabia; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. Electronic address: zmemish@yahoo.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32387694

Citation

Hashem, Anwar M., et al. "Therapeutic Use of Chloroquine and Hydroxychloroquine in COVID-19 and Other Viral Infections: a Narrative Review." Travel Medicine and Infectious Disease, vol. 35, 2020, p. 101735.
Hashem AM, Alghamdi BS, Algaissi AA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Med Infect Dis. 2020;35:101735.
Hashem, A. M., Alghamdi, B. S., Algaissi, A. A., Alshehri, F. S., Bukhari, A., Alfaleh, M. A., & Memish, Z. A. (2020). Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. Travel Medicine and Infectious Disease, 35, 101735. https://doi.org/10.1016/j.tmaid.2020.101735
Hashem AM, et al. Therapeutic Use of Chloroquine and Hydroxychloroquine in COVID-19 and Other Viral Infections: a Narrative Review. Travel Med Infect Dis. 2020 May - Jun;35:101735. PubMed PMID: 32387694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. AU - Hashem,Anwar M, AU - Alghamdi,Badrah S, AU - Algaissi,Abdullah A, AU - Alshehri,Fahad S, AU - Bukhari,Abdullah, AU - Alfaleh,Mohamed A, AU - Memish,Ziad A, Y1 - 2020/05/06/ PY - 2020/04/19/received PY - 2020/04/28/revised PY - 2020/04/29/accepted PY - 2020/5/11/pubmed PY - 2020/7/11/medline PY - 2020/5/11/entrez KW - COVID-19 KW - Chloroquine KW - Hydroxychloroquine KW - SARS-CoV-2 SP - 101735 EP - 101735 JF - Travel medicine and infectious disease JO - Travel Med Infect Dis VL - 35 N2 - The rapidly spreading Coronavirus Disease (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus (SARS-CoV-2), represents an unprecedented serious challenge to the global public health community. The extremely rapid international spread of the disease with significant morbidity and mortality made finding possible therapeutic interventions a global priority. While approved specific antiviral drugs against SARS-CoV-2 are still lacking, a large number of existing drugs are being explored as a possible treatment for COVID-19 infected patients. Recent publications have re-examined the use of Chloroquine (CQ) and/or Hydroxychloroquine (HCQ) as a potential therapeutic option for these patients. In an attempt to explore the evidence that supports their use in COVID-19 patients, we comprehensively reviewed the previous studies which used CQ or HCQ as an antiviral treatment. Both CQ and HCQ demonstrated promising in vitro results, however, such data have not yet been translated into meaningful in vivo studies. While few clinical trials have suggested some beneficial effects of CQ and HCQ in COVID-19 patients, most of the reported data are still preliminary. Given the current uncertainty, it is worth being mindful of the potential risks and strictly rationalise the use of these drugs in COVID-19 patients until further high quality randomized clinical trials are available to clarify their role in the treatment or prevention of COVID-19. SN - 1873-0442 UR - https://www.unboundmedicine.com/medline/citation/32387694/Therapeutic_use_of_chloroquine_and_hydroxychloroquine_in_COVID_19_and_other_viral_infections:_A_narrative_review_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1477-8939(20)30214-3 DB - PRIME DP - Unbound Medicine ER -